Coracten XL

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coracten XL

This section provides a factual overview of Coracten XL, defining its identity, composition, and pharmacological classification for informational purposes.

Property Description
Active ingredient Nifedipine
Form Modified-release tablet (XL)
Pharmacological class Calcium Channel Blocker (Dihydropyridine)
Origin Synthetic
General purpose Supports stable cardiovascular function

What Type of Medicine is Coracten XL?

Coracten XL is a prescription-only medicine whose active component is Nifedipine, a synthetic compound that belongs to the Dihydropyridine family. It is classified as a Calcium Channel Blocker (CCB). This pharmacological group is clinically recognized for its action on vascular smooth muscle, making it a valuable tool in adult pharmacotherapy. Unlike many other cardiovascular agents, Nifedipine focuses on blood vessel relaxation, offering a specific profile of action often required in managing complex cardiovascular conditions.

Coracten XL: Composition and Purpose of the 'XL' Designation

The medication is formulated as a distinct modified-release tablet, designed for oral administration. The designation "XL" is a key differentiating factor, signaling this sustained-release formulation which ensures the dose is delivered slowly and consistently. This specific controlled-release design is crucial for delivering the Nifedipine consistently. This formulation maintains stable drug levels, which is vital for patients requiring reliable, long-acting support for their cardiovascular system over a full 24-hour period.

General Benefit: How Coracten XL Supports Cardiovascular Function

The fundamental general benefit of Coracten XL is the reduction of the heart's workload through vascular smooth muscle relaxation. This relaxation causes vasodilation (widening of blood vessels), which in turn decreases systemic vascular resistance (SVR). Nifedipine reduces this resistance, which is the primary mechanism by which the drug functions as an antihypertensive agent and provides antianginal benefits, offering foundational support to regulate blood flow and cardiac function.

Regulatory References

  1. Nifedipine: MedlinePlus Drug Information

What side effects are possible with Coracten XL?

Possible Side Effects and Safety Information

The safety profile for Coracten XL (Nifedipine prolonged-release) is based on data documented in official government regulatory sources, detailing adverse reactions by frequency and organ system.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to frequency, with the most common generally related to the drug's vasodilatory effects:

Frequency Common Adverse Reactions
Very Common (≥ 1/10) Oedema, Peripheral oedema (swelling)
Common (≥ 1/100 to <1/10) Headache, Dizziness, Palpitations, Flushing, Constipation, Malaise

Less common reactions (Uncommon and Rare) include allergic reactions, visual disturbances, hypotension, and transient increases in liver enzymes.

Serious Adverse Reactions and Restrictions

Regulators have documented several serious adverse reactions, though they are typically rare. These include severe hypersensitivity reactions like anaphylactic shock or angioedema, blood disorders such as agranulocytosis, and severe skin reactions like toxic epidermal necrolysis. Deterioration of heart failure has also been observed in patients with poor cardiac reserve.

Contraindications (situations where the drug must not be used) include cardiogenic shock, unstable angina, use within one month of a myocardial infarction, concomitant use with the medicine rifampicin, and during pregnancy or breastfeeding.

Safety requires caution in patients with hepatic impairment, as dose reduction may be necessary, and in the elderly. The medicine must not be taken with grapefruit juice, which can significantly alter its concentration in the body. Prolonged use has been rarely associated with gingival hyperplasia (gum overgrowth).

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Coracten XL (Nifedipine Extended Release) overdosage is based on authoritative government regulatory documents.

Overdosage with nifedipine can lead to severe cardiovascular events, necessitating immediate medical attention and active cardiovascular support.

Documented Overdose Manifestations

Symptoms may range from milder effects to profound systemic issues. Documented presentations include disturbances of consciousness, generalized edema, dizziness, tachycardia, or bradycardia. Severe manifestations documented are profound hypotension, cardiogenic shock, and coma.

Physiological systems affected may include the cardiovascular and central nervous systems, which can lead to cerebral or myocardial ischemia as a result of the excessive drop in blood pressure.

Emergency Actions and Monitoring

When to seek help: Overdosage requires immediate medical contact and the initiation of active cardiovascular support, with continuous monitoring of cardiovascular and respiratory function.

Required Interventions: Management often involves supportive measures such as fluid administration, pressor agents, and the judicious use of calcium infusion.

Observation: For sustained-release preparations, regulatory guidance specifies that patients who are asymptomatic must be observed for an extended period, typically 12 hours, to account for delayed drug release.

Decontamination: Measures like activated charcoal or gastric lavage are considered only within one hour of ingestion and based on the severity of the potentially toxic amount consumed.

Therapeutic Uses of Coracten XL

What Coracten XL Treats: Main Uses and Benefits

Coracten XL is commonly used for the long-term management of essential hypertension (chronic high blood pressure) and is relevant for easing recurrent chest pain (Angina Pectoris). Its therapeutic focus is aligned with established clinical guidance for these primary cardiovascular conditions.

The medication is generally applied in contexts where a consistent, sustained therapeutic effect is considered relevant, managing conditions presenting with systemic imbalance and episodic or fluctuating manifestations. It is used to help address the symptoms related to increased physiological tension in the circulatory system and to support the maintenance of controlled blood pressure, thereby assisting with maintaining functional stability.

Coracten XL may assist with easing symptoms related to physical discomfort, specifically the recurrent cluster of chest discomfort or tightness that arises during stable angina episodes. The therapeutic benefit may include reducing the frequency and severity of angina attacks, easing the symptom burden during activity, and contributing to day-to-day comfort.

“The sustained-release formulation is commonly applied to support chronic cardiovascular well-being through continuous symptomatic management.”

Quick Fact: Relief for Chronic Cardiovascular Symptoms
Primary Therapeutic Uses Essential hypertension, chronic stable angina, and vasospastic angina.
Key Patient Benefit Supports the maintenance of stable blood pressure and helps reduce the occurrence of chest pain.

Regulatory References

  1. Nifedipine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Coracten XL?

The population eligibility for Coracten XL (Nifedipine Extended-Release) is strictly defined by regulatory labeling, outlining groups who are permitted, restricted, or absolutely prohibited from use.

Contraindicated Populations

The medicine is contraindicated and must not be used by patients with known hypersensitivity to Nifedipine or other dihydropyridines, or those experiencing cardiogenic shock, unstable angina, or a myocardial infarction within the last month. Use is also prohibited in patients with clinically significant aortic stenosis or any form of gastrointestinal obstruction (including Kock pouch). Concomitant use with Rifampicin is strictly contraindicated.

Age and Life-Stage Restrictions

Coracten XL is approved for use in adults. It is not recommended for use in children and adolescents (under 18 years old), as safety and efficacy have not been established. The medicine is contraindicated during pregnancy and not recommended while breastfeeding.

Conditional Use and Special Caution

Patients with impaired hepatic function require the medicine to be used with caution and close monitoring, as dose reduction may be necessary. Caution is also advised for patients with poor cardiac reserve (e.g., heart failure) or severe hypotension.

What should I know about interactions with other medicines?

Coracten XL Interactions with other medicines and products

Coracten XL (Nifedipine) interaction patterns are strictly defined by regulatory authorities based on alterations in drug concentration or additive pharmacological effects.

Documented Pharmacokinetic Interactions

Nifedipine is primarily metabolized through the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong inducers or inhibitors of this enzyme can significantly alter Nifedipine exposure.

Substance Type Interaction Outcome (Official Description)
Strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) Contraindicated due to risk of total loss of Nifedipine efficacy from severely reduced plasma concentration.
CYP3A4 Inhibitors (e.g., Itraconazole, Ritonavir) Causes an increase in Nifedipine plasma concentrations and systemic exposure.

Pharmacodynamic and Clearance Restrictions

Co-administration with other hypotensive agents, including Beta-Blockers, may result in an additive hypotensive effect, requiring monitoring as documented in official labeling. Nifedipine may also decrease the clearance of co-administered drugs like Digoxin, potentially leading to increased Digoxin plasma concentrations.

Food and Herbal Product Constraints

Ingestion of Grapefruit or Grapefruit Juice must be avoided because it is documented to inhibit the CYP3A4 pathway, resulting in a significant, approximately two-fold increase in Nifedipine exposure (Cmax). Co-administration with the herbal product St. John’s Wort is also restricted due to its potent CYP3A4 induction, which reduces Nifedipine effectiveness.

Population-Specific Note

Administration to patients with moderate or severe Hepatic Impairment should be avoided due to the documented increase in drug half-life and systemic exposure.

Mechanism of Action

The mechanism of Nifedipine (Coracten XL) involves the regulation of ion movement, which dictates the activity of vascular smooth muscle.

Inhibition of Vascular Calcium Channels

The core action involves the inhibition of the L-type voltage-dependent calcium channel ( Cav1 family) found in the walls of arterial blood vessels. Nifedipine acts as an antagonist, binding to the channel and preventing the inward flow of calcium ions ( Ca^2+). This molecular event directly suppresses the calcium-dependent pathway necessary for sustained muscle contraction, leading to the relaxation of vascular smooth muscle.

Decrease in Systemic Vascular Resistance

The resulting vasodilation (widening) of the peripheral arterioles causes a fundamental decrease in Systemic Vascular Resistance (SVR), which represents the total pressure the heart must work against. By reducing this resistance, the drug decreases the mechanical workload placed upon the heart muscle. The extended-release (XL) formulation ensures this blockade is gradual and consistent, thereby influencing the expression of the mechanism and mitigating the intensity of the body’s counter-regulatory response, such as reflex sympathetic activation.

Modulation of Coronary Blood Flow

The mechanism also involves the relaxation and widening of the coronary arteries that supply blood to the heart itself. This action increases the capacity for oxygen-rich blood delivery to the heart muscle, contributing to the overall physiological change resulting from the reduction in systemic resistance.

Dosage and Administration Information

Administration and Dosing Principles

Coracten XL is administered once daily (q24 h) via the oral route as a modified-release tablet, which is designed to provide sustained delivery of nifedipine. The standard practice is to take the dose at approximately the same time each day to ensure stable concentration levels throughout the 24-hour period. The tablet must be swallowed whole with liquid and should not be chewed, divided, or crushed, as this action would compromise the controlled-release mechanism of the formulation.


Official Dosing and Adjustment

Administration typically begins with a defined starting dose, often 30 mg or 60 mg, which is then gradually adjusted over time. The dosage may be increased, or titrated, every 7 to 14 days, as necessary, with the aim of reaching a dose within the maintenance range, which commonly extends up to 90 mg per day. Maximum approved daily doses can range up to 120 mg, depending on the specific product and indication. The medication may be taken either with or without food.

Handling and Timing Official Administration Constraint
Tablet Integrity Must be swallowed whole; do not crush or chew.
Beverage Restriction Concomitant use with grapefruit juice is specifically avoided.
Missed Dose Skip the missed dose and resume the schedule; do not take a double dose.

Use in Specific Populations

Official labeling addresses use in certain patient groups, recommending caution and potentially lower maintenance doses for older adults. For patients with hepatic impairment (liver function issues), a reduced starting dose and careful monitoring are generally advised. The safety and efficacy of Coracten XL have not been established in patients under 18 years of age, and therefore, use in this population is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coracten XL


Evidence for Use in Managing Essential Hypertension

Research has explored the use of modified-release nifedipine (Coracten XL) in conditions characterized by systemic or functional imbalance, such as chronic high blood pressure, also known as essential hypertension. Researchers primarily used Randomized Controlled Trials (RCTs) and meta-analyses to evaluate the long-acting formulation against placebo or other treatments. These studies monitored outcomes related to physiological strain by measuring changes in both systolic and diastolic blood pressure (BP).

Studies reported measurements that demonstrated changes in both systolic and diastolic BP across the 24-hour dosing interval in the studied populations. This research highlights changes measured during the study period, helping to contextualize the patterns observed regarding BP stability. Furthermore, research examined data related to the incidence of major cardiovascular events—such as stroke or heart attack—over extended periods. Data related to these long-term outcomes are often derived from pooled data and systematic reviews that combine findings across similar medications.

Evidence for Use in Chronic Stable Angina

The modified-release formulation was studied for use in patients with chronic stable angina, a condition characterized by fluctuating or episodic manifestations of chest pain. These studies primarily monitored patient-reported outcomes describing perceived discomfort by measuring the frequency and reported severity of angina attacks. Research also examined outcomes reflecting daily functioning by testing and documenting the amount of time patients could exercise.

Clinical trials reported measurements related to the frequency of documented angina attacks and measurements of functional capacity during standardized testing. A key aspect of the research involved focusing on the profile of the sustained-release formulation to distinguish its data from the historical reports associated with the immediate-release version.

Evidence Gaps and Areas of Uncertainty

What remains uncertain is that definitive evidence from a single, dedicated long-term RCT focused solely on Coracten XL is not fully established for verifying major cardiovascular event reduction. Comparative evidence is lacking for some combinations of existing treatments. Data for certain groups remain insufficient, especially for specific comorbid conditions. The research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References Modified-Release Nifedipine: A Review of its Use in the Management of Hypertension and Angina Pectoris

Frequently Asked Questions (FAQ)

Common questions about Coracten XL (FAQ)


Q: Can Coracten XL cause swelling in the ankles or feet, and is this temporary?

Peripheral oedema, which is swelling, particularly in the ankles or feet, is listed as a very common side effect in official safety information. This occurs because the medicine causes blood vessels to widen. Official information suggests that for some individuals, these common side effects may be mild and can lessen or resolve within a few weeks as the body adjusts.


Q: Why does Coracten XL sometimes cause headaches when a person first starts taking it?

Headache is listed as a common adverse reaction in official product information. Headache is understood to be related to the medicine’s primary action of relaxing and widening blood vessels (vasodilation), which can influence blood flow patterns.


Q: How long does Coracten XL generally take to show its full effect on blood pressure?

According to official documents on administration principles, dosage adjustments are typically made gradually, often over 7 to 14 days. The adjustment period aims to establish consistent and stable concentration levels of the medication over a 24-hour period.


Q: Why is it important to continue taking Coracten XL even if a person feels well?

Coracten XL is used to manage chronic conditions like high blood pressure and chest pain (angina), which often have no noticeable symptoms. Regulatory information emphasizes that the treatment controls these conditions but does not cure them. Stopping treatment should only be done in consultation with a healthcare professional.


Q: Can Coracten XL affect the appearance of a person's gums (gingival hyperplasia)?

Official safety data confirms that prolonged use of nifedipine has been rarely associated with gingival hyperplasia. This is a condition where the gum tissue may overgrow. If changes in the gums are observed, official guidance directs consulting a healthcare professional.


Q: What is the significance of the drug being metabolized by the CYP3A4 system?

Coracten XL is broken down in the body primarily by an enzyme system called CYP3A4. This is significant because many other medicines, foods, and supplements can interfere with this system. Such interference can lead to an alteration in the concentration of nifedipine circulating in the blood.


Q: Can Coracten XL affect a person's ability to drive or operate machinery?

Official information advises that Coracten XL may cause side effects such as dizziness, lightheadedness, or visual disturbances. Regulatory advice states that caution should be exercised regarding driving or operating machinery if a person experiences these symptoms, particularly when treatment is initiated or after a dose change.


Q: What precautions are necessary for patients with existing liver problems taking Coracten XL?

Official documents advise that caution is necessary and close monitoring is recommended for patients with existing liver problems (hepatic impairment). The management of patients with hepatic impairment, including potential dose adjustments, requires close professional monitoring to account for altered processing of the medicine.


Q: How is Coracten XL different from the regular, immediate-release Coracten or other nifedipine forms?

The key difference lies in the release mechanism. The 'XL' formulation uses a specific, controlled delivery system to release the active ingredient (nifedipine) slowly and consistently over a 24-hour period. Immediate-release forms, in contrast, release the drug quickly, which can cause faster and potentially more variable changes in drug concentration.


Q: Is it typical to experience dizziness or lightheadedness when starting Coracten XL?

Dizziness and lightheadedness are listed as common adverse reactions in the official safety profile. These symptoms are related to the medicine's effect on blood pressure and may occur more frequently when treatment is first started or when the dosage is increased.


Q: Does Coracten XL affect a person's heart rate or cause palpitations?

Palpitations (a fast or irregular heartbeat) are listed as a common adverse reaction. While the extended-release formula aims for stable delivery, safety information notes a potential for a temporary reflex increase in heart rate.


Q: Is Coracten XL used to treat conditions other than high blood pressure or angina?

Official literature primarily focuses on the use of nifedipine for high blood pressure and angina. However, regulatory-aligned information also sometimes mentions the drug for the management of Raynaud's phenomenon, a condition affecting blood flow to the fingers and toes.


Q: Are there any dietary restrictions or foods to avoid while on Coracten XL?

The only food product specifically restricted and documented in regulatory documents is grapefruit or grapefruit juice. This is because consuming grapefruit can cause a significant alteration in the amount of nifedipine in the bloodstream.


Q: What are the signs of a possible allergic reaction to Coracten XL?

Signs of a serious allergic reaction documented in regulatory materials may include severe reactions such as swelling of the face, eyes, lips, or tongue. Other serious symptoms to be aware of include difficulty breathing or swallowing, the development of a rash, or hives.


Q: Is there a risk of developing a low blood pressure (hypotension) while using this medication?

Hypotension (low blood pressure) is listed as an uncommon adverse reaction in the official safety profile. Official warnings state that excessive drops in blood pressure have been reported, particularly when treatment is started or when the dose is increased.


Q: Does Coracten XL contain lactose or other ingredients people might be intolerant to?

Official product information, typically found in the list of inactive ingredients, confirms that the formulation of Coracten XL contains lactose monohydrate (a type of milk sugar). The full composition, including any other excipients, is detailed in the official package literature.


Q: Can taking Coracten XL cause or worsen feelings of fatigue or tiredness?

Official safety information lists adverse effects such as malaise (a general feeling of discomfort or uneasiness), dizziness, and unusual weakness or tiredness. These effects may contribute to feelings of fatigue.


Q: Are there any known interactions between Coracten XL and herbal supplements?

Regulatory documents explicitly mention a contraindication with the herbal product St. John’s Wort. This is due to its documented effect on the CYP3A4 enzyme system, which can severely reduce the effectiveness of Coracten XL.


Q: Is Coracten XL a long-term treatment, or can it be stopped after a certain period?

This medication is intended for the long-term control of chronic conditions like high blood pressure and angina. Regulatory-aligned information advises that treatment may be continued indefinitely. It is important that the medicine not be stopped suddenly, but rather in consultation with a healthcare professional.


Q: Are there common side effects that tend to go away after a few weeks of use?

Official safety information indicates that if mild side effects are experienced, such as headaches, dizziness, or mild swelling, they may often be temporary. For some patients, these side effects can lessen or resolve within a few weeks of use as the body adjusts to the medicine.


Q: Does Coracten XL have any impact on sexual ability or desire?

Decreased sexual ability or desire is listed as a potential side effect in official safety information. If this effect is experienced, it is noted as a less common possibility.


Q: Is a person more likely to experience side effects when the Coracten XL dose is increased?

Official warnings state that side effects, particularly those related to changes in blood pressure like hypotension (very low blood pressure) or dizziness, are more likely to occur when the drug is first started or when the dosage is increased.


Q: Does Coracten XL cause constipation, and if so, what is the reason?

Constipation is listed as a common adverse reaction in the official safety profile. This effect is understood to be related to the medicine’s mechanism of blocking calcium channels, which may inhibit the motor activity of the colon.


Q: Can Coracten XL worsen acid reflux or cause heartburn?

Heartburn is explicitly listed as a potential side effect of the medication in official safety information.


Q: Are there reports of Coracten XL affecting mood or causing anxiety?

Official safety data lists adverse reactions in the psychiatric disorders category, including reports of nervousness and mood changes.


Q: Does Coracten XL interact with common antidepressants or other psychiatric medications?

Regulatory sources mention that certain antidepressant medicines, such as fluoxetine and nefazodone, can potentially affect the way nifedipine works. Due to possible changes in concentration, professional monitoring may be required when taking these medications together.


Q: Is Coracten XL used for the treatment of Raynaud's phenomenon?

Nifedipine is sometimes mentioned in official literature for the treatment of Raynaud's syndrome or phenomenon, in addition to its primary approved uses for high blood pressure and angina.


Q: Does Coracten XL affect the results of any routine medical lab tests?

Official regulatory information has noted rare, usually transient, elevations of certain liver enzymes, such as AST and ALT, in laboratory results. However, the direct relationship between these changes and the drug is often uncertain.


Q: Is there a known effect of Coracten XL on fertility or sperm function?

Regulatory-aligned information indicates there is no clear evidence to suggest that nifedipine reduces fertility in either men or women.


Q: Can Coracten XL cause a person to feel generally unwell or have flu-like symptoms?

Malaise, which is defined as a general feeling of discomfort, illness, or uneasiness, is listed as a common adverse reaction in official safety documents.


Q: Does Coracten XL carry an increased risk of sun sensitivity or sunburn?

Official safety information includes rare reports of photosensitivity reactions, which means an increased sensitivity to the sun.


Q: What is the risk of a temporary increase in chest pain (angina) when starting the drug?

Official safety information lists an increase in the frequency or severity of chest pain as a serious side effect. There have been rare reports of worsening chest pain (angina) and heart attack in people with severe heart disease. These reports have been noted in safety data, particularly around the time treatment is started.


Q: What is the difference between Coracten XL and other similar brand names like Adalat CC or Procardia XL?

Coracten XL, Adalat CC, and Procardia XL are all different brand names for extended-release formulations of the same active ingredient, nifedipine. While they share the same drug, regulatory documents note that the specific controlled-release mechanisms and pill designs can differ, potentially leading to varied drug concentration profiles in the blood.


Q: How should I dispose of unused or expired Coracten XL?

Unused or expired medicine must not be thrown away via wastewater or normal household waste. Official guidelines advise patients to follow specific disposal instructions on the drug labeling or to seek advice from a pharmacist or other healthcare professional regarding proper, safe disposal methods.

How should Coracten XL be stored and disposed of?

Coracten XL Storage and Disposal Instructions

Coracten XL (Nifedipine modified-release) requires specific storage and handling rules to maintain its stability, as mandated by regulatory documents.


Storage Conditions

Requirement Official Rule
Temperature Do not store the medicine above 25°C and keep from freezing
Protection Store in the original package, protected from light, heat, and moisture
Child Safety Keep the medicine out of the sight and reach of children
Stability Do not use the tablets after the expiry date (EXP)

Disposal Requirements

Official guidelines state that medicines must not be thrown away via wastewater or household waste. Unused or expired Coracten XL must be discarded safely; seek instruction from a healthcare professional or pharmacist on proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coracten XL found in:

A-Z Index: